Scholarlink

Introduction <p>The COVID-19 pandemic and liver diseases both cause significant metabolic disturbances, yet the specific mechanisms driving these changes remain poorly understood.</p> Objectives <p>This study aimed to elucidate and compare the urinary metabolomic profiles of COVID-19 patients, individuals with liver diseases, and healthy controls to determine common and unique metabolic signatures between diseases.</p> Methods <p>Untargeted metabolomic profiling was performed using liquid chromatography–mass spectrometry (LC-MS) on urine samples from COVID-19 patients (n = 102), liver disease patients (n = 100), and healthy controls (n = 101). Differential metabolite abundance, pathway enrichment, network topology, and Random Forest–based machine learning analyses were performed.</p> Results <p>Both COVID-19 and liver disease exhibited extensive metabolic reprogramming. COVID-19 patients showed suppression of Vitamin B6 and purine metabolism, indicating impaired energy production and antioxidant defense. Liver disease patients exhibited reduced primary bile acid biosynthesis and pantothenate metabolism, reflecting hepatic dysfunction. Random Forest models robustly discriminated disease from healthy states, with binary models for COVID-19 and liver disease achieving AUCs of 0.998, and a multiclass model distinguishing all three groups with 91.9% accuracy. Both conditions shared perturbations in amino acid and steroid-related pathways, reflecting common systemic stress. Importantly, unique metabolites, such as N-Acetylvaline, Succinyladenosine, and S-adenosylhomocysteine in COVID-19, and 3-Hydroxysebacic acid, Asn-Trp, and bile acid derivatives in liver disease, emerged as highly specific biomarkers, highlighting systemic viral stress versus chronic hepatic metabolic adaptation and warranting future validation.</p> Conclusion <p>These findings enhance our understanding of disease-specific metabolic remodelling and point to potential biomarkers for diagnosis and therapeutic targeting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative urinary metabolomics reveals unique and shared pathways in COVID-19 and liver diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月27日

查看全文
  • Garima Juyal,
  • Fariya Khan,
  • Sidra Siddiqui,
  • Ayyub Rehman,
  • Arumugam Madhumalar,
  • Neda Mirsamadi,
  • Gagan Deep Jhingan,
  • Chhagan Bihari,
  • Mohan Chandra Joshi

摘要

Introduction

The COVID-19 pandemic and liver diseases both cause significant metabolic disturbances, yet the specific mechanisms driving these changes remain poorly understood.

Objectives

This study aimed to elucidate and compare the urinary metabolomic profiles of COVID-19 patients, individuals with liver diseases, and healthy controls to determine common and unique metabolic signatures between diseases.

Methods

Untargeted metabolomic profiling was performed using liquid chromatography–mass spectrometry (LC-MS) on urine samples from COVID-19 patients (n = 102), liver disease patients (n = 100), and healthy controls (n = 101). Differential metabolite abundance, pathway enrichment, network topology, and Random Forest–based machine learning analyses were performed.

Results

Both COVID-19 and liver disease exhibited extensive metabolic reprogramming. COVID-19 patients showed suppression of Vitamin B6 and purine metabolism, indicating impaired energy production and antioxidant defense. Liver disease patients exhibited reduced primary bile acid biosynthesis and pantothenate metabolism, reflecting hepatic dysfunction. Random Forest models robustly discriminated disease from healthy states, with binary models for COVID-19 and liver disease achieving AUCs of 0.998, and a multiclass model distinguishing all three groups with 91.9% accuracy. Both conditions shared perturbations in amino acid and steroid-related pathways, reflecting common systemic stress. Importantly, unique metabolites, such as N-Acetylvaline, Succinyladenosine, and S-adenosylhomocysteine in COVID-19, and 3-Hydroxysebacic acid, Asn-Trp, and bile acid derivatives in liver disease, emerged as highly specific biomarkers, highlighting systemic viral stress versus chronic hepatic metabolic adaptation and warranting future validation.

Conclusion

These findings enhance our understanding of disease-specific metabolic remodelling and point to potential biomarkers for diagnosis and therapeutic targeting.